We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2011 by Mahidol University.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: January 27, 2011
Last Update Posted: January 27, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Mahidol University
January 25, 2011
January 27, 2011
January 27, 2011
January 2011
January 2012   (Final data collection date for primary outcome measure)
Ocular surface index score [ Time Frame: 1 month ]
Same as current
No Changes Posted
Eye lid inflammation, corneal staining score, tear break up time and tear volume [ Time Frame: 1 month ]
Same as current
Not Provided
Not Provided
Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma
Effect of Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% in the Treatment of Ocular Surface Disease in Glaucoma Patients
To study effect of hydroxypropylmethylcellulose 0.3% and sodium hyaluronate 0.18% in the treatment of ocular surface disease in glaucoma patients.
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Ocular Surface Disease
  • Glaucoma
  • Drug: hydroxypropylmethylcellulose
    TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
  • Drug: sodium hyaluronate
    QID to every 2 hous, 1-2 drops per each time, duration 1 month
  • Experimental: TearA
    Intervention: Drug: hydroxypropylmethylcellulose
  • Experimental: TearB
    Intervention: Drug: sodium hyaluronate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
February 2012
January 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • OSDI > or equal 20 and eye lid inflammation , meibomian gland inflammation,conjunctival injection,follicle at tarsus , positive corneal staining , tear break up time less than 8 seconds , tear volume less than 5.5 mm.

Exclusion Criteria:

  • Age below 18 yo
  • Active infectious corneal disease
  • Post penetrating keratoplasty or glaucoma drainage device
  • Known allergy to medication
  • Lactation , Pregnant
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
AssocProf Pinnita Tanthuvanit, Department of Ophthalmology
Mahidol University
Not Provided
Principal Investigator: AssocProf Pinnita Tanthuvanit, MD Mahidol University
Mahidol University
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP